Ideaya Biosciences Inc (IDYA)

Jan 03, 2025

IDEAYA Biosciences (NASDAQ:IDYA) Sees Strong Trading VolumeWhat's Next? - MarketBeat

Jan 03, 2025

Jan 02, 2025

Pfizer exits Sangamo pact; Roche, Ideaya strike ADC deals - BioPharma Dive

Jan 02, 2025

Jan 02, 2025

IDEAYA Biosciences in-licenses Hengrui’s SHR-4849 - The Pharma Letter

Jan 02, 2025

Dec 31, 2024

Ideaya, Hengrui join hands in $1B deal for phase I ADC targeting DLL3 - BioWorld Online

Dec 31, 2024

Dec 31, 2024

IDEAYA Biosciences Enters into Exclusive License Agreement with Hengrui Pharma - Defense World

Dec 31, 2024

Dec 30, 2024

IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors - Kilgore News Herald

Dec 30, 2024

Dec 30, 2024

IDEAYA Biosciences (NASDAQ:IDYA) Sets New 12-Month LowHere's Why - MarketBeat

Dec 30, 2024

Dec 30, 2024

Ideaya Biosciences stock hits 52-week low at $24.38 - Investing.com

Dec 30, 2024

Dec 30, 2024

BTIG maintains buy on Ideaya stock, target at $62 By Investing.com - Investing.com Canada

Dec 30, 2024

Dec 29, 2024

IDEAYA Biosciences (IDYA): A Down Year Presents a Window of Opportunity for Investors - MSN

Dec 29, 2024

Dec 29, 2024

IDEAYA Secures Global Rights to Promising Cancer Drug SHR-4849 with 73% Response Rate in SCLC Trial - StockTitan

Dec 29, 2024

Dec 29, 2024

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Kilgore News Herald

Dec 29, 2024

Dec 25, 2024

IDEAYA Announces Agenda for Investor R&D Day Webcast on December 16, 2024 - cnhinews.com

Dec 25, 2024

Dec 23, 2024

Jane Street Group LLC Trims Stock Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - MarketBeat

Dec 23, 2024

Dec 22, 2024

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Stock Holdings Increased by Geode Capital Management LLC - MarketBeat

Dec 22, 2024

Dec 21, 2024

Barclays PLC Purchases 118,438 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - MarketBeat

Dec 21, 2024

Dec 20, 2024

Wellington Management Group LLP Trims Stock Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - MarketBeat

Dec 20, 2024

Dec 19, 2024

IDEAYA Biosciences (NASDAQ:IDYA) Sets New 52-Week LowHere's Why - MarketBeat

Dec 19, 2024

Dec 19, 2024

IDEAYA Biosciences Announces Late-Breaker Oral Presentation of IDE397 Phase 1 Expansion Results in MTAP-Deletion Lung and Urothelial Cancer at the 36th Edition of the EORTC-NCI-AACR Symposium - The Eastern Progress Online

Dec 19, 2024

Dec 18, 2024

IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer - The Eastern Progress Online

Dec 18, 2024

Dec 17, 2024

Ideaya Biosciences keeps stock target, Outperform on robust medicine pipeline - Investing.com Canada

Dec 17, 2024

Dec 17, 2024

IDEAYA Biosciences (NASDAQ:IDYA) Receives "Overweight" Rating from Cantor Fitzgerald - MarketBeat

Dec 17, 2024

Dec 17, 2024

Ideaya nominates KAT6/7 inhibitor as development candidate - BioWorld Online

Dec 17, 2024

Dec 17, 2024

Short Interest in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Declines By 11.2% - MarketBeat

Dec 17, 2024

Dec 17, 2024

IDEAYA Biosciences (NASDAQ:IDYA) Receives "Outperform" Rating from Wedbush - MarketBeat

Dec 17, 2024

Dec 17, 2024

IDEAYA Announces IDMC Recommendation of Move-Forward Dose in Par - GuruFocus.com

Dec 17, 2024

Dec 17, 2024

IDEAYA Announces IDMC Recommendation of Move-Forward Dose in Part 2a of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative Metastatic Uveal Melanoma - Quantisnow

Dec 17, 2024

Dec 17, 2024

IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers - The Malaysian Reserve

Dec 17, 2024

Dec 16, 2024

IDEAYA nominates IDE251 for cancer treatment development By Investing.com - Investing.com South Africa

Dec 16, 2024

Dec 16, 2024

IDEAYA Announces Development Candidate Nomination of IDE251, a P - GuruFocus.com

Dec 16, 2024

Dec 16, 2024

IDEAYA nominates IDE251 for cancer treatment development - Investing.com

Dec 16, 2024

Dec 16, 2024

IDEAYA's Novel Cancer Drug Shows Promise for Breast & Lung Cancer Treatment - StockTitan

Dec 16, 2024

Dec 16, 2024

IDEAYA Biosciences (NASDAQ:IDYA) pulls back 9.2% this week, but still delivers shareholders solid 23% CAGR over 5 years - Yahoo Finance

Dec 16, 2024

Dec 16, 2024

Indo-Asian News Service - IANS India Pvt Ltd

Dec 16, 2024

Dec 16, 2024

State Street Corp Boosts Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - MarketBeat

Dec 16, 2024

Dec 16, 2024

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives $53.67 Consensus Price Target from Analysts - MarketBeat

Dec 16, 2024

Dec 15, 2024

(IDYA) Proactive Strategies - Stock Traders Daily

Dec 15, 2024

Dec 14, 2024

IDEAYA Biosciences (NASDAQ:IDYA) Hits New 52-Week LowShould You Sell? - MarketBeat

Dec 14, 2024

Dec 13, 2024

IDEAYA Announces Webcast to Report Interim Phase 2 Data for Darovasertib and Regulatory Update from FDA Type C Meeting in Neoadjuvant Uveal Melanoma on Monday, September 23, 2024 - Kilgore News Herald

Dec 13, 2024

Dec 13, 2024

IDEAYA Biosciences to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference - The Eastern Progress Online

Dec 13, 2024

Dec 13, 2024

Ideaya Biosciences stock hits 52-week low at $25.16 - Investing.com India

Dec 13, 2024

Dec 13, 2024

Ideaya Biosciences stock hits 52-week low at $25.16 By Investing.com - Investing.com UK

Dec 13, 2024

Dec 13, 2024

IDEAYA Biosciences' SWOT analysis: precision oncology stock poised for growth - Investing.com

Dec 13, 2024

Dec 12, 2024

BNP Paribas Financial Markets Decreases Stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - MarketBeat

Dec 12, 2024